Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend - 2The Best Cell phone Brands for Tech Aficionados
- 3When will the Epstein files be released — and will they reveal anything new?
- 4UN mission says no evidence Hezbollah rearming in southern Lebanon
- 5Winter solstice 2025 marks the shortest day of the year in the Northern Hemisphere today
- An Ideal Getaway - Spots for Solo Travel
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- New research reveals urban raccoons across the US show early signs of domestication
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Fake new headlights rule steer Australian drivers astray
- New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- ChatGPT served as "suicide coach" in man's death, lawsuit alleges
- Israel approves 19 new West Bank settlements in major annexation push
- The 15 Best Business visionaries Under 40
